The veterinary vaccine manufacturers industry in DACH is essential for animal health, focusing on the development of vaccines to prevent diseases in livestock and pets. Companies in this sector range from biotech startups to established pharmaceutical firms, offering a variety of products to tackle both viral and bacterial infections in animals. With advancements in technology and increasing awareness of animal welfare, this industry is poised for growth, aiming to enhance vaccine efficiency and efficacy. Furthermore, the rise of zoonotic diseases underscores the importance of this market, propelling innovation in vaccine manufacturing and research.


The investors in the veterinary vaccine industry within DACH represent a mix of venture capital and corporate entities, primarily based in Germany and Switzerland. The firms vary in size, with many managing substantial portfolios since their inception, ranging from the late 1990s to the 2010s. In 2024, these investors collectively made significant contributions across a spectrum of veterinary-focused companies, demonstrating a commitment to advancing animal health innovations. Their interests reflect a blend of expertise in biotechnology and pharmaceuticals, enhancing the potential for strategic partnerships and funding.


Top 11 Veterinary Vaccine Manufacturers Investors in DACH


1. Wellington Partners


Wellington Partners is a Munich-based venture capital firm founded in 1998, specializing in life sciences investments. The firm focuses on early- and growth-stage companies, providing both capital and strategic support to entrepreneurs in sectors such as therapeutics and medical devices. Notably, Wellington Partners has been involved in significant funding rounds for companies like MinervaX, which raised substantial amounts for the development of a vaccine candidate aimed at preventing life-threatening infections in newborns. This involvement in vaccine development highlights their commitment to supporting innovative healthcare solutions, which may also encompass veterinary vaccine technologies as they continue to explore opportunities in the life sciences sector.


2. Boehringer Ingelheim Venture Fund

  • Website: boehringer-ingelheim-venture.com
  • Type: Venture Capital
  • Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
  • Founded year: 2010
  • Headcount: 11-50
  • Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm founded in 2010, based in Ingelheim Am Rhein, Germany. The fund specializes in investing in pioneering science and biotechnology innovations, particularly in the healthcare sector. It provides both capital and expertise to startups, helping them develop and commercialize their products. Notably, the fund has participated in significant transactions such as the seed financing round for Delonix Bioworks, which is focused on building synthetic biology vaccine platforms, and the funding round for Ruipeng Pet Healthcare, a company dedicated to improving pet healthcare services. These investments highlight the fund's interest in innovative healthcare solutions, including those applicable to veterinary vaccines.


3. Nestlé

  • Website: nestle.com
  • Type: Corporate
  • Headquarters: Vevey, Vaud, Switzerland
  • Founded year: 1866
  • Headcount: 10001+
  • Number of deals in 2024: 2
  • LinkedIn: nestle-s-a-

Nestlé S.A. is a multinational food and beverage company based in Vevey, Vaud, Switzerland, founded in 1866. The company offers a diverse range of products, including coffee, dairy, and pet care items, and operates globally with a commitment to sustainability. In the veterinary context, Nestlé has made strategic investments and acquisitions that highlight its engagement in the sector. Notably, it acquired Ralston Purina Company in 2001, which is known for its pet food and veterinary products. Additionally, Nestlé has participated in significant funding rounds for veterinary care providers such as IVC Evidensia and Independent Vetcare, indicating its active role in supporting the veterinary industry. Furthermore, Nestlé is an existing investor in Prometheus Biosciences, a biotechnology firm, showcasing its interest in health-related sectors, including veterinary vaccines.


4. Bayern Kapital

  • Website: bayernkapital.de
  • Type: Venture Capital
  • Headquarters: Landshut, Bavaria, Germany
  • Founded year: 1995
  • Headcount: 11-50
  • Number of deals in 2024: 27
  • LinkedIn: bayern-kapital-gmbh

Bayern Kapital is a venture capital firm based in Landshut, Bavaria, Germany, founded in 1995. The firm specializes in providing investment and growth capital to innovative high-tech startups and scale-ups, particularly in the life sciences and software sectors. Bayern Kapital supports its clients with financial resources and access to a network of industry experts, helping them navigate growth challenges. Among their notable transactions, they participated in funding rounds for companies like Immunic AG and SIRION BIOTECH. SIRION BIOTECH, in particular, is relevant as it focuses on viral vector platforms and has been involved in developing new vector technologies for the vaccine industry, highlighting Bayern Kapital's engagement in the life sciences and vaccine development sectors.


5. Verve Ventures

  • Website: verve.vc
  • Type: Venture Capital
  • Headquarters: Zurich, Zurich, Switzerland
  • Founded year: 2010
  • Headcount: 11-50
  • Number of deals in 2024: 25
  • LinkedIn: investiere-venture-capital

Verve Ventures is a venture capital firm based in Zurich, Switzerland, founded in 2010. The firm specializes in deep tech investments across Europe, providing funding and strategic support to science and technology startups. Their focus spans various sectors, including climate tech, industrial technology, and health & bio. Notably, Verve Ventures has invested in Piavita, a company that raised $3 million in a Series A round in 2019 and $1,031,825 in a Seed Round in 2016, both of which are relevant to the veterinary field. Additionally, they participated in funding rounds for Hylomorph, which, while not directly a veterinary vaccine manufacturer, operates in the health sector and may have applications in veterinary medicine. This involvement in companies that intersect with veterinary technology positions Verve Ventures as a potential investor in the veterinary vaccine manufacturers space.


6. Nestlé Health Science


Nestlé Health Science is a corporate investor based in Lausanne, Vaud, Switzerland, specializing in health and nutrition. Founded in 2011, the company focuses on medical nutrition, active lifestyle nutrition, and pharmaceuticals, aiming to improve health outcomes for patients and consumers. With a global presence, Nestlé Health Science serves various customer segments, including healthcare professionals and individuals seeking nutritional support. Notably, they have made significant investments in the healthcare sector, including the acquisition of Prometheus Biosciences and Aimmune Therapeutics, which are focused on medical therapies. Importantly, they also invested in Ruipeng Pet Healthcare, a company that operates in the pet healthcare market, indicating their interest in veterinary-related sectors. This diverse investment portfolio highlights their commitment to science-based solutions and innovative products, which may extend to veterinary vaccines as part of their broader strategy in pet health.


7. Partners Group

  • Website: partnersgroup.com
  • Type: Private Equity
  • Headquarters: Baar, Zug, Switzerland
  • Founded year: 1996
  • Headcount: 1001-5000
  • Number of deals in 2024: 19
  • LinkedIn: partners-group

Partners Group Holding AG is a prominent investment management firm based in Baar, Zug, Switzerland, specializing in private equity, private infrastructure, private real estate, and private debt. Founded in 1996, the firm manages over USD 149 billion in assets and is recognized for its innovative investment strategies and commitment to sustainability. Notably, Partners Group has made significant investments in the pet care sector, acquiring Wedgewood Pharmacy, which operates at the intersection of pet care and healthcare, and Blue River PetCare, valued at over $440 million. These acquisitions highlight their strategic interest in veterinary-related businesses, positioning them as a key player in the veterinary vaccine manufacturers industry.


8. IBB Ventures


IBB Ventures is a venture capital firm based in Berlin, Germany, founded in 1997. The firm specializes in early-stage financing and has invested in over 270 startups, providing not only capital but also expertise and resources to help these businesses thrive in competitive markets. Among their notable transactions, IBB Ventures has invested in vetevo, a company that raised funds in seed rounds in 2018 and 2019, focusing on veterinary solutions. This involvement highlights their interest in the veterinary sector, particularly in innovative startups that may contribute to advancements in veterinary vaccines and related fields.


9. Pureos Bioventures


Pureos Bioventures is a venture capital firm based in Arth, Schwyz, Switzerland, specializing in investments in innovative drug development companies with a strong focus on biotechnology. The firm provides capital and strategic guidance to its portfolio companies to help advance their therapeutic solutions for severe diseases. In 2022, Pureos Bioventures co-led a financing round for Minervax, a Danish biotech company, which raised €72M ($76.5M) to support the late-stage development of its GBS vaccine candidate, aimed at preventing life-threatening infections in newborns. This investment highlights Pureos's engagement in the vaccine development space, which is relevant to veterinary vaccine manufacturers. Additionally, they have been involved in various other biotech investments, indicating a broad interest in the life sciences sector.


10. Creathor Ventures

  • Website: creathor.com
  • Type: Venture Capital
  • Headquarters: Bad Homburg, Hesse, Germany
  • Founded year: 2003
  • Headcount: 11-50
  • LinkedIn: creathor-venture

Creathor Ventures is a venture capital firm based in Bad Homburg, Hesse, Germany, founded in 2003. The firm specializes in providing funding and strategic support to startups in the technology and healthcare sectors. With a portfolio that includes companies like CEVEC Pharmaceuticals, Creathor Ventures has demonstrated a commitment to advancing healthcare innovations, particularly in the field of vaccines. CEVEC Pharmaceuticals, which has received multiple rounds of funding from Creathor, focuses on the commercialization of vaccines and protein technologies, utilizing their proprietary CAP® Technology platform. This involvement highlights Creathor's engagement in the vaccine sector, including potential veterinary applications. Additionally, Creathor has participated in funding rounds for other biotech firms, such as Sirion Biotech, which, while not directly related to veterinary vaccines, showcases their broader interest in biopharmaceutical innovations.


11. Boehringer Ingelheim


Boehringer Ingelheim, founded in 1885 and based in Ingelheim Am Rhein, Germany, is a leading pharmaceutical company that specializes in developing and manufacturing medications for both human and animal health. The company has a strong emphasis on research and development, aiming to innovate and improve health outcomes across various therapeutic areas, including respiratory diseases and oncology. In recent years, Boehringer Ingelheim has made significant acquisitions to enhance its portfolio, including the acquisition of AMAL Therapeutics and ViraTherapeutics, both focused on cancer immunotherapy. While these transactions are primarily in the oncology space, Boehringer Ingelheim's commitment to animal health and their established presence in the veterinary market indicate their potential relevance to veterinary vaccine manufacturers. Their investments in companies like NBE-Therapeutics, which is involved in immunotherapy, further demonstrate their strategic focus on innovative health solutions, which could extend to veterinary applications.



Veterinary Vaccine Manufacturers Insights: Key Investors in DACH


InvestorHeadquarterSizeFoundedDeals 2024
Wellington PartnersMunich, Bavaria, Germany11-5019989
Boehringer Ingelheim Venture FundIngelheim Am Rhein, Rhineland-Palatinate, Germany11-5020105
NestléVevey, Vaud, Switzerland10001+18662
Bayern KapitalLandshut, Bavaria, Germany11-50199527
Verve VenturesZurich, Zurich, Switzerland11-50201025
Nestlé Health ScienceLausanne, Vaud, Switzerland10001+20112
Partners GroupBaar, Zug, Switzerland1001-5000199619
IBB VenturesBerlin, Berlin, Germany11-50199718
Pureos BioventuresArth, Schwyz, Switzerland11-507
Creathor VenturesBad Homburg, Hesse, Germany11-5020030
Boehringer IngelheimIngelheim Am Rhein, Rhineland-Palatinate, Germany10001+18852


Want to find more investors focusing on the veterinary vaccine manufacturers industry?

If you want to find more investors that are active in the veterinary vaccine manufacturersindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!